Introducing EpiFinder™ Genome

The First Commercial High-throughput,
Multiplex ChIP-seq Kit for Epigenetics

quantitative ChIP-seq tracks
0

A comprehensive solution for genome-wide profiling, our EpiFinder™ Genome kit with multiplexed ChIP-seq offers intrinsically quantitative comparisons across up to 24 samples or replicates, reduced background noise, and greater specificity compared to state-of-the-art approaches.

The kit includes reagents and a detailed protocol for generating sequencing-ready Illumina libraries, yielding up to 24×8=192 quantitative ChIP-seq tracks and corresponding inputs from just 125,000 cells per final ChIP-seq track. A customized analysis pipeline enables an automated analysis workflow from FASTQ to demultiplexed and quantitative data for up to 192 genome-wide profiles, offering in-depth insights into epigenetic studies.

  • Easy to use
  • 3-day, 14-hour hands-on pooled workflow
  • 1 M cells/sample requirement for profiling up to 8 hPTMs
  • Validated with cells and tissue
  • Validated with native and fixed starting material
Built on our innovative EpiFinder™ platform with our proprietary hmqChIP-seq and LACODE technologies, our EpiFinder™ family of kits scale from genome-wide detail with high sequencing depth to global quantifications based on low-depth sequencing.

Coming Soon!

EpiFinder™ Global

The first hmqChIP-seq technology for global screening, EpiFinder™ Global offers a highly multiplexed workflow and the ability to easily quantify global hPTM and DNAme levels in up to 96 samples. EpiFinder™ Global delivers accurate results from affordable, low-depth next-generation sequencing, while allowing internal quality control of antibody specificity, saving time and resources without compromising quality.

Coming Soon!

EpiFinder™ cNUC

EpiFinder™ cNUC is the first multiplexed hPTM and DNAme profiling solution for cell-free nucleosomes found in liquid biopsies such as blood plasma. Save precious material and cut costs by multiplexing up to 24 samples in the same sequencing libraries.

This website uses cookies. By continuing to use this site, you accept our use of cookies.